Skip to content
TREVENTIS™ Corporation
  • Home
  • About Us
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Dual Aβ/ tau oligomer inhibitor
    • Broad spectrum TDP oligomer inhibitor
    • p53 oligomer inhibitor
  • Technology
    • Protein Misfolding: The Basics
    • Treventis’ CCM Technology
  • Therapeutic Areas
    • Alzheimer’s Disease and Tauopathy
    • Amyotrophic Lateral Sclerosis (ALS)
    • Parkinson’s Disease
    • Cancer
  • News & Publications
    • News
    • Publications
    • Social Media
  • Careers
  • Partners & Collaborators
  • Contact Us
TREVENTIS™ Corporation
TREVENTIS™ Corporation > Therapeutic Areas
  • Share
             
  • Print

Therapeutic Areas

Our discovery platform can identify compounds that potently block the progression of amyloid toxicity. These compounds can be designed with selectivity toward a particular misfolding protein (narrow spectrum) or with polypharmocology (broad spectrum), for proteins implicated in over 160 rare/orphan diseases and major indications including

  • Therapeutic Areas
  • Alzheimer’s Disease and Tauopathy
  • Amyotrophic Lateral Sclerosis (ALS)
  • Parkinson’s Disease
  • Cancer
    • Therapeutic Areas
    • Alzheimer’s Disease and Tauopathy
    • Amyotrophic Lateral Sclerosis (ALS)
    • Parkinson’s Disease
    • Cancer

Quick Links

  • Home
  • About Us
  • Contact Us

Social Links

  • Twitter
  • Linkedin
Copyright © Treventis Corporation. | Site Map
Website by Axxiem